BioCentury
ARTICLE | Financial News

Atara prices $127.8M follow-on

January 4, 2018 9:28 PM UTC

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $127.8 million through the sale of 7 million shares at $18.25 in a bumped-up follow-on underwritten by JPMorgan, Cowen, William Blair and Canaccord Genuity. The price is a slight premium to Atara's close of $18.10 on Tuesday, when it proposed after market hours to raise $100 million.

On Dec. 29, Atara gained 19% to $18.10 after it said FDA cleared it to begin the open-label Phase III MATCH and ALLELE trials of tabelecleucel (formerly ATA129) to treat Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (EBV-PTLD) refractory to Rituxan rituximab. The company started both trials this week, and expects top-line data in 1H19 (see BioCentury Extra, Dec. 29, 2017)...

BCIQ Company Profiles

Atara Biotherapeutics Inc.